MEDVi QUAD New Formula 2026: Apomorphine Replaces PT-141 in Updated 4-in-1 Compounded ED Treatment

NEWARK, Del., September 16, 2026 (Newswire.com) - Quick disclosure: this is a paid advertorial, and a commission is earned if you enroll through links here. Claims below are attributed to MEDVi, not independently endorsed. QUAD is a compounded prescription product - available only after a licensed provider evaluates you, and approval isn't guaranteed. It's not FDA-approved; compounded medications aren't reviewed by the FDA for safety, effectiveness, or quality before reaching patients. Official site: quad.medvi.org. Details below reflect brand materials reviewed in September 2026.

MEDVi QUAD New Formula Consumer Research 2026: Researching This 4-in-1 Compounded ED Treatment, Verified - Ingredients, Pricing, and Reviewing What Actually Changed

You saw an ad for MEDVi QUAD - a private telehealth path to a prescription ED treatment, no waiting room, no awkward in-person visit. A short online evaluation, review by a licensed provider, and if approved, medication delivered straight to your door. That's the pitch, and for the right candidate, it's a genuinely convenient way to start a clinician-guided conversation. Here's what MEDVi actually offers, what's confirmed about the current formula, and what's worth knowing before you enroll.

See if you qualify for MEDVi QUAD

What MEDVi QUAD Offers

• A private path to treatment - online evaluation instead of an in-person visit
• A 4-in-1 compounded formula - sildenafil, tadalafil, PT-141, and L-citrulline in a single sublingual dose
• Fast, discreet delivery - shipped directly if approved, per MEDVi
• Ongoing support - MEDVi describes 24/7 medical support and the ability to cancel anytime
• Straightforward pricing - starting at $114/month, as currently displayed

The Confirmed 2026 Formula

MEDVi has directly confirmed the current, partner-approved formula for QUAD:

• Sildenafil - the active ingredient behind Viagra's approved use, positioned by MEDVi for peak response
• Tadalafil - the active ingredient behind Cialis's approved use, with a response window MEDVi describes as up to 36 hours
• PT-141 (bremelanotide) - added in this update, working through a different pathway than the other three
• L-Citrulline - supporting nitric-oxide-related blood flow alongside sildenafil

This is a genuine step up from MEDVi's earlier formula, which paired sildenafil and tadalafil with vardenafil and apomorphine. If you're comparing coverage, this is the version to act on.

View current MEDVi QUAD pricing and formula details

Smart-Buyer Check: Why Some Sources Still Show the Old Formula

Here's the one thing worth knowing before you enroll, and it works in your favor to check it: MEDVi's own public page hasn't been fully caught up with this update. As of this article's most recent check in September 2026, the live page still displayed the previous apomorphine-based formula, even though MEDVi has directly confirmed PT-141 as current.

• Why it matters: an older screenshot, article, or webpage isn't proof of what you'll actually receive
• What to do: confirm the formula shown during your evaluation and check it against your dispensed label - that's the detail that actually governs what ships to you
• The upside: being the reader who checks this is exactly how you get the confirmed, current formula instead of an outdated version other buyers might assume is still accurate

Ingredient Breakdown

Sildenafil

A PDE5-inhibitor active ingredient used in FDA-approved ED products. That approval applies to sildenafil individually - not to the finished, compounded QUAD combination.

Tadalafil

A longer-acting PDE5 inhibitor; MEDVi states it stays active for up to 36 hours. Same principle: individual approval doesn't transfer to the compounded product.

Sildenafil and Tadalafil Together - Worth Raising With Your Provider

• Both are PDE5 inhibitors, each individually FDA-approved
• Sildenafil's FDA label: avoid use with other PDE5 inhibitors
• Tadalafil's FDA label: safety and efficacy with another PDE5 inhibitor haven't been studied; patients advised not to combine
• That labeling covers each drug alone - it doesn't evaluate a compounded product built around combining them, and this article draws no conclusion about MEDVi's formulation from it
• Bring this up directly during your evaluation - it's exactly the kind of detail a prescribing clinician is there to weigh

PT-141 (Bremelanotide)

• MEDVi describes PT-141 as acting through the central nervous system, independent of blood flow - the piece of the formula addressing the desire side, not just the physical response
• The only FDA-approved bremelanotide product, Vyleesi, is an injectable indicated for a specific condition in premenopausal women
• Vyleesi's label states it is not indicated for men or for enhancing intimate performance, and lists transient blood-pressure increases, nausea, and cardiovascular restrictions
• That approval, population, route, and indication are distinct from compounded sublingual PT-141 for men's ED - Vyleesi's efficacy or dosing data is not evidence for how PT-141 performs in QUAD

L-Citrulline

• An amino acid MEDVi describes as supporting nitric-oxide-related blood flow
• A small study of 24 men with mild ED (1.5g/day oral L-citrulline) reported improvement in hardness scores for some participants, with authors calling for further research
• That's ingredient-level, small-sample research - not a QUAD trial, and QUAD's own dose hasn't been disclosed, so it shouldn't be assumed to match the study dose

How It Works

MEDVi markets the sublingual format as bypassing first-pass digestion, with onset described as beginning within roughly 10-15 minutes - no swallowing a pill and waiting. That's MEDVi's own marketing claim, attributed here, not independently confirmed for the finished formulation.

Pricing and Subscription

• Starting price: $114/month, as displayed on MEDVi's page
• Reference price shown: $179/month - a brand-displayed figure, not an independently verified market benchmark
• Price checked: September 2026 - confirm the current amount at consultation or checkout

Start your MEDVi QUAD evaluation now

Refund and Cancellation - What MEDVi's Policy Says

• Cancel anytime, but submit the request at least 72 hours before your next billing date or the upcoming cycle is still charged
• Cancel within the first 72 hours of a subscription, before receiving any services: eligible for a full refund
• Provider disqualification: can trigger a refund under the applicable subscription terms
• Multi-month subscriptions: unused, unshipped months may be eligible for a refund
• Outside those circumstances: no refund issued, and consultation fees are non-refundable

Is MEDVi QUAD FDA-Approved?

No. QUAD is a compounded formulation, and FDA states that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing the way FDA-approved drugs are.

Eligibility and Medication Interactions

• Eligibility and dosing are determined by the prescribing clinician - not by this article
• FDA-approved sildenafil/tadalafil labeling identifies nitrate use as contraindicated due to blood-pressure-drop risk
• Disclose all current medications, including nitrates, clearly during intake

Before You Enroll: Quick Verification Checklist

• Formula at checkout: confirm PT-141 (not apomorphine) appears on your actual order and label
• Prescribing entity: not confirmed as QUAD-specific - ask MEDVi directly
• Medication interactions: disclose everything you're currently taking
• Compounding pharmacy: not publicly named - ask which one fulfills your order
• Refund terms: confirm the terms that apply to your specific subscription length

Get started with MEDVi QUAD

MEDVi QUAD Contact Information

• Email: hello@medvi.org
• Phone (QUAD/MEDVi product page): (585) 312-4226
• Mailing address: 131 Continental Dr. Ste 305, Newark, DE 19713 USA
• Official website: quad.medvi.org

Fast Facts

• Product: MEDVi QUAD
• Category: Compounded prescription ED treatment (telehealth)
• Confirmed formula: Sildenafil, Tadalafil, PT-141, L-Citrulline
• Delivery: Sublingual liquid
• Brand-stated onset: ~10-15 minutes (unverified brand claim)
• Starting price: $114/month ($179/month reference)
• Cancellation notice: 72 hours before billing
• FDA status: Compounded, not FDA-approved as a finished product

Frequently Asked Questions

What ingredients are in MEDVi QUAD in 2026?

Sildenafil, tadalafil, PT-141, and L-citrulline - per MEDVi's confirmed current, partner-approved formula.

Why do different sources list different MEDVi QUAD ingredients?

MEDVi's public materials haven't consistently shown the current formula. MEDVi has directly confirmed sildenafil, tadalafil, PT-141, and L-citrulline as governing, but some pages and earlier coverage still reference the previous vardenafil/apomorphine formula.

Does MEDVi QUAD still contain Apomorphine?

MEDVi has confirmed the current formula uses PT-141, not apomorphine. As of this article's most recent check, MEDVi's public page still displayed apomorphine - confirm the formula shown during prescribing and on your label.

Is MEDVi QUAD FDA-approved?

No. It's a compounded formulation, and compounded drugs aren't FDA-approved or FDA-reviewed for safety, effectiveness, or quality before marketing.

Is a prescription required?

Yes - available only after online evaluation and approval by a licensed provider, if clinically appropriate. Approval isn't guaranteed.

How much does it cost?

Starting at $114/month against a $179/month reference price, as of September 2026. Confirm current pricing at consultation or checkout.

Is MEDVi QUAD the same as Viagra or Cialis?

No. Sildenafil and tadalafil are ingredients associated with those approved medications, but QUAD is a separate compounded formulation that isn't itself FDA-approved.

The Bottom Line

MEDVi QUAD packages a 4-in-1 compounded approach into a private, telehealth-first experience: online evaluation, licensed provider review, and discreet delivery if approved. The current, MEDVi-confirmed formula - sildenafil, tadalafil, PT-141, L-citrulline - is a real update from the version some sources are still showing, and checking that you're getting the current version is a five-minute step that's well worth taking. As a compounded product, QUAD isn't FDA-approved, and eligibility and dosing are the prescribing clinician's call - but for the right candidate, this is exactly the kind of structured, provider-guided path worth a closer look.

See if you qualify for MEDVi QUAD

Additional MEDVi QUAD Coverage: Readers comparing sources may find earlier MEDVi QUAD buyer-verification coverage useful for background on provider review, pharmacy fulfillment, and cancellation terms, and a separate earlier account of the formula change itself. Both reflect the formula as understood at the time of publication and are worth reading alongside this piece.

Email: hello@medvi.org
Phone: +1-585-312-4226
MEDVI Mailing Address: 131 Continental Dr. Ste 305, Newark, DE 19713 USA

Disclaimers

• Material Limitations:
  • Based on MEDVi's product page (checked multiple times, September 2026), MEDVi's Terms and Refund policies, direct MEDVi partner confirmation of the current formula, FDA drug labeling, and published research
  • No product testing was performed
  • Brand claims (onset, performance descriptions) are attributed to MEDVi, not independently verified
  • MEDVi has confirmed sildenafil, tadalafil, PT-141, and L-citrulline as current; public display of that formula has been inconsistent - the page showed apomorphine as of this article's latest check
  • The clinician network evaluating QUAD patients hasn't been confirmed as QUAD-specific and is described generically
  • The dispensing compounding pharmacy wasn't named in materials reviewed
  • Any fact that couldn't be confirmed has been omitted rather than assumed
• Forward-Looking Statements: This article reflects information available and confirmed as of September 2026. Specifications, pricing, formulation, and policies may change after publication - rely on MEDVi's official site and direct confirmation for current information.
• Marketing Language Notice: Attribution language throughout identifies statements as originating from MEDVi. Promotional phrases referenced are brand-asserted marketing language, not independent findings by this publication.
• Trademark Acknowledgment: QUAD® and MEDVi® are trademarks of their respective owners. Viagra®, Cialis®, and Levitra® are registered trademarks of their respective manufacturers, referenced for factual comparison only; no affiliation or endorsement is implied.
• Geographic and Jurisdiction Notice: Availability, pricing, and regulations may vary by state and are subject to change. This article does not constitute legal, medical, or regulatory advice for any jurisdiction.

SOURCE: MEDVi

Source: MEDVi